Filing Flows › Xeris Biopharma Holdings (XERS) › Q2 2025
Xeris Biopharma Holdings (XERS) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Xeris Biopharma Holdings (XERS) reported revenue of $71.5M for the second quarter 2025 (Q2 2025), +49% from a year earlier and +19% from the quarter before. Operating margin was 6.3%, net loss $1.9M (2.7% of revenue).
Xeris Biopharma Holdings, Q2 2025: revenue $71.5M (+49% year over year), operating margin 6.3%, net loss $1.9M, operating cash flow $182K. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $71.5M | +19% | +49% |
| Operating profit | $4.5M | — | — |
| Net earnings | −$1.9M | — | — |
| Operating cash flow | $182K | — | — |
What changed
Revenue was $71.5M in Q2 2025, up 49% year over year and up 19% from the previous quarter. Recorlev was the largest line at 44% of revenue. Recorlev added $18.1M year over year (up 136%), 77% of the total change. Keveyis declined 13%.
Operating profit was $4.5M, a 6.3% margin (up 23.3 points year over year). Total costs grew 19% against revenue growth of 49%. The fastest-growing cost line was Cost of revenue (+53%). The quarter ended with a net loss of $1.9M, narrower than the previous quarter's $9.2M loss. Net interest and other expense of $6.4M was the main reason.
Operating cash flow was $182K. Non-cash charges added back $325K of depreciation and amortization and $5.0M of share-based compensation. Working capital and other items used $3.2M.
Questions
What was Xeris Biopharma Holdings' revenue in the second quarter 2025?
Xeris Biopharma Holdings (XERS) reported revenue of $71.5M for the second quarter 2025 (Q2 2025), +49% from a year earlier and +19% from the quarter before.
Was Xeris Biopharma Holdings profitable in the second quarter 2025?
Operating profit was $4.5M (6.3% of revenue) and net loss $1.9M.